Business Segments · Other Operating Income
BioPharma Systems — Other Operating Income
This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ2 2026May 7, 2026
Rolls up toOther operating expenses
How to read this metric
Large negative values may indicate one-time charges or restructuring costs, while positive values may indicate non-recurring gains.
Detailed definition
This represents miscellaneous operating income or expenses that are not classified as cost of goods sold, SG&A, or R&D f...
Peer comparison
Commonly found in segment reporting for large corporations to capture non-core operating items.
Metric ID:
bdx_segment_biopharma_systems_other_operating_income_expense_netHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 |
Range$0.00 – $0.00
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — other operating income?
- Becton, Dickinson and Company (BDX) reported biopharma systems — other operating income of $0.00 in Q1 2026.
- What does biopharma systems — other operating income mean?
- Net miscellaneous operating income or expenses for the BioPharma Systems segment.